Moleculin Biotech Set to Shine at Upcoming Conference
Moleculin Biotech, Inc. (NASDAQ: MBRX), a prominent player in the pharmaceutical industry, is gearing up for a significant appearance at the forthcoming 37th Annual ROTH Conference. The company specializes in developing therapies aimed at difficult-to-treat tumors and various viral infections.
Fireside Chat Details
This noteworthy event will take place on a Tuesday, and Walter Klemp, the company's Chairman and CEO, will be engaging in a live webcast fireside chat. This presentation is scheduled to begin at 11:00 AM PT. Attendees can look forward to insightful discussions regarding Moleculin's innovative approaches to oncology.
Engagement Opportunities for Investors
In addition to the fireside chat, Moleculin is committed to connecting with the investment community. Executives from the company will be available for one-on-one meetings with qualified investors registered for the conference. Such direct engagements facilitate meaningful exchanges about the company's progress and objectives.
Accessing the Conference
For those interested in following along, details of the event can be found on the conference website. There will also be a live webcast of the fireside chat available on the company's official website under their Events section, making it accessible for a broader audience.
About Moleculin Biotech, Inc.
Moleculin Biotech operates at the Phase 3 clinical stage, primarily focusing on a dynamic pipeline targeting challenging tumors and viral diseases. Their lead compound, Annamycin, represents a new generation of anthracyclines designed to overcome multidrug resistance and minimize cardiotoxic effects associated with standard chemotherapy drugs.
Clinical Trials and Research Advancements
The company is set to launch the MIRACLE Trial (Moleculin R/R AML AnnAraC Clinical Evaluation, MB-108) to evaluate Annamycin in combination with cytarabine—collectively termed AnnAraC. This pivotal Phase 3 trial is crucial as it aims to establish new treatment protocols for relapsed or refractory acute myeloid leukemia (AML). Following the encouraging results from prior clinical studies, Moleculin is optimistic about moving towards potential regulatory approval.
Further Developments at Moleculin
Alongside Annamycin, Moleculin is also advancing WP1066, an immune/transcription modulator that targets brain tumors and other cancers by inhibiting oncogenic transcription factors like p-STAT3 while igniting a natural immune response. In addition, the company is expanding its portfolio with antimetabolites such as WP1122, which may hold promise in treating viral infections as well as certain cancer types.
Connecting with Moleculin
For further insights into the company's mission, progress, and innovations, stakeholders and interested parties are encouraged to visit Moleculin's official website. They can also connect with the company through social media platforms like X, LinkedIn, and Facebook to remain updated on the latest developments and announcements.
Frequently Asked Questions
When is Moleculin Biotech presenting at the ROTH Conference?
Moleculin Biotech will present at the 37th Annual ROTH Conference, with a fireside chat scheduled for Tuesday at 11:00 AM PT.
Who will be representing Moleculin at the conference?
Walter Klemp, the Chairman and Chief Executive Officer of Moleculin, will be participating in the fireside chat.
What is the focus of Moleculin's research?
Moleculin focuses on developing therapies for hard-to-treat tumors and viral infections, including leading treatments like Annamycin.
How can investors meet with Moleculin's management?
Qualified investors registered for the conference can arrange one-on-one meetings with the company’s management.
Where can I find more information about Moleculin's events?
Details about Moleculin's events and webcast access can be found on their official website under the Events section.
